Enliven Therapeutics Inc. (ELVN) — Cash Flow-to-Debt Ratio
Enliven Therapeutics Inc. (ELVN) has a Cash Flow-to-Debt Ratio of -1.68x as of March 2026, meaning its operating cash flow of $-19.29 Million could theoretically repay -2% of its total liabilities ($11.49 Million) in one year. See Enliven Therapeutics Inc. short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Enliven Therapeutics Inc. Cash Flow-to-Debt Ratio (2017–2025)
Historical debt coverage capacity for Enliven Therapeutics Inc. across 9 annual periods. Also explore ELVN shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Enliven Therapeutics Inc. (2017–2025)
Year-by-year debt coverage analysis for Enliven Therapeutics Inc.. For market capitalisation and broader financial context, see ELVN stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.22x | $-70.30 Million | $16.68 Million | ▲ +8.3% |
| 2024 | -4.60x | $-73.19 Million | $15.91 Million | ▼ -94.9% |
| 2023 | -2.36x | $-61.27 Million | $25.96 Million | ▼ -1078.1% |
| 2022 | -0.20x | $-32.08 Million | $160.12 Million | ▲ +93.2% |
| 2021 | -2.96x | $-19.13 Million | $6.47 Million | ▼ -122.3% |
| 2020 | -1.33x | $-8.53 Million | $6.41 Million | ▲ +73.3% |
| 2019 | -4.99x | $-21.88 Million | $4.38 Million | ▼ -4.2% |
| 2018 | -4.79x | $-8.78 Million | $1.83 Million | ▲ +19.0% |
| 2017 | -5.91x | $-8.79 Million | $1.49 Million | — |